Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
38 Leser
Artikel bewerten:
(0)

Quantitative Immunoassay Life Science Dashboard: A 48-Question Survey Completed by 592 Scientists - Research and Markets

DUBLIN, Apr. 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Quantitative Immunoassay Life Science Dashboard Series 3" report to their offering.

Research and Markets Logo

Immunoassays are commonly used laboratory tests for identification and quantification of proteins. With a range of applications in diagnosis of cancer, immunology and disease research, immunoassays are widely used by scientists in academia and industry.

The 2016 Quantitative Immunoassay Dashboard is the third in a series that characterizes the dynamic market for immunoassay products.

This 2016 Dashboard provides a snapshot of the current market landscape that is compared with data from all of the previous Quantitative Immunoassay Dashboards , and was developed from responses to a 48-question survey completed by 592 scientists located in North America and Europe.

This Dashboard reveals key market indicators for the Quantitative Immunoassay market as a whole as well as for the following techniques representing market sub-segments:

- Colorimetric ELISA
- Chemiluminescent ELISA
- Fluorescent ELISA
- Electrochemiluminescence immunoassays
- Bead-based immunoassays
- This report is focused on the use of Quantitative Immunoassay products in life science research market.

The following suppliers were surveyed for this report:

- Abcam
- Affymetrix/eBioscience
- BD Biosciences
- Bio-Rad
- GE Healthcare/Amersham
- KPL/SeraCare
- Luminex (direct)
- Meso Scale Discovery
- Perkin Elmer
- R&D Systems/Biotechne
- Roche Applied Science
- Sigma/EMD Millipore
- Thermo Fisher Scientific (including Life Technologies, Pierce, Invitrogen, Novex, Molecular Probes)

Key Topics Covered:

1. Executive Summary

2. Dashboard "At A Glance"

3. Market Opportunity Matrix

4. Respondent Qualification

5. Demographics

6. Frequency of Performance: Life Science Techniques

7. Frequency of Use: Immunoassay Methods & Additional Protein Related Method

8. Co-Performance: Quantitative Immunoassay Methods & Life Science Techniques

9. Throughput, Growth Rates, Price & Monthly Spend

10. Market Size

11. Percentage of Spend with Suppliers of Immunoassay Products

12. Customer Satisfaction & Interest in Switching

13. Product Feature Influencing Purchase Decisions

14. Primary Focus/Application of Protein Analysis Research & Use of Protein Classes/Categories

15. Desired Changes to Immunoassay Products

16. Appendix I: Supporting Data

17. Appendix II: The Capabilities and Life Science Dashboards TM Available

Companies Mentioned

- Abcam
- Affymetrix/eBioscience
- BD Biosciences
- Bio-Rad
- GE Healthcare/Amersham
- KPL/SeraCare
- Luminex (direct)
- Meso Scale Discovery
- Perkin Elmer
- R&D Systems/Biotechne
- Roche Applied Science
- Sigma/EMD Millipore
- Thermo Fisher Scientific (including Life Technologies, Pierce, Invitrogen, Novex, Molecular Probes)

For more information about this report visit http://www.researchandmarkets.com/research/w73jmf/quantitative

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.